 | • レポートコード：MRC2012B1230 • 出版社/出版日：GlobalInfoResearch / 2020年12月28日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥515,040 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥772,560 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,030,080 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートでは、統合失調症治療薬の世界市場を広く調査・分析し、今後の市場展望をまとめております。統合失調症治療薬の種類別市場規模（第一世代抗精神病薬、第二世代抗精神病薬、第三世代抗精神病薬）、用途別市場規模（病院、診療所、その他）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェアなどの情報を掲載しています。 ・市場概要 ・企業情報（販売量、市場シェア、製品概要、SWOT分析）：AstraZeneca、Bristol-Myers Squibb、Johnson & Johnson、Eli Lilly、Amgen、GlaxoSmithKline、AbbVie、Alkermes、 ・地域別グローバル市場分析 2015年-2020年 ・統合失調症治療薬の北米市場（アメリカ、カナダ、メキシコ） ・統合失調症治療薬のヨーロッパ市場（ドイツ、イギリス、フランス、ロシア、イタリア） ・統合失調症治療薬のアジア市場（中国、日本、韓国、インド、東南アジア、オーストラリア） ・統合失調症治療薬の南米市場（ブラジル、アルゼンチン） ・統合失調症治療薬の中東・アフリカ市場（サウジアラビア、トルコ、エジプト、南アフリカ） ・種類別分析：第一世代抗精神病薬、第二世代抗精神病薬、第三世代抗精神病薬 ・用途別分析：病院、診療所、その他 ・地域別市場規模予測 2021年-2025年 ・調査の結果・結論 |
Market Overview
The global Schizophrenia Therapeutics market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019.
The Schizophrenia Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
Market segmentation
Schizophrenia Therapeutics market is split by Type and by Application. For the period 2015-2025, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
By Type, Schizophrenia Therapeutics market has been segmented into:
First-Generation Antipsychotic Drugs
Second-Generation Antipsychotic Drugs
Third-Generation Antipsychotic Drugs
By Application, Schizophrenia Therapeutics has been segmented into:
Hospitals
Clinics
Other
Regions and Countries Level Analysis
Regional analysis is another highly comprehensive part of the research and analysis study of the global Schizophrenia Therapeutics market presented in the report. This section sheds light on the sales growth of different regional and country-level Schizophrenia Therapeutics markets. For the historical and forecast period 2015 to 2025, it provides detailed and accurate country-wise volume analysis and region-wise market size analysis of the global Schizophrenia Therapeutics market.
The report offers in-depth assessment of the growth and other aspects of the Schizophrenia Therapeutics market in important countries (regions), including:
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Competitive Landscape and Schizophrenia Therapeutics Market Share Analysis
Schizophrenia Therapeutics competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Schizophrenia Therapeutics sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2015-2020, this study provides the Schizophrenia Therapeutics sales, revenue and market share for each player covered in this report.
The major players covered in Schizophrenia Therapeutics are:
AstraZeneca
Bristol-Myers Squibb
Johnson & Johnson
Eli Lilly
Amgen
GlaxoSmithKline
AbbVie
Alkermes
Table of Contents
1 Schizophrenia Therapeutics Market Overview
1.1 Product Overview and Scope of Schizophrenia Therapeutics
1.2 Classification of Schizophrenia Therapeutics by Type
1.2.1 Global Schizophrenia Therapeutics Revenue by Type: 2015 VS 2019 VS 2025
1.2.2 Global Schizophrenia Therapeutics Revenue Market Share by Type in 2019
1.2.3 First-Generation Antipsychotic Drugs
1.2.4 Second-Generation Antipsychotic Drugs
1.2.5 Third-Generation Antipsychotic Drugs
1.3 Global Schizophrenia Therapeutics Market by Application
1.3.1 Overview: Global Schizophrenia Therapeutics Revenue by Application: 2015 VS 2019 VS 2025
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Other
1.4 Global Schizophrenia Therapeutics Market by Regions
1.4.1 Global Schizophrenia Therapeutics Market Size by Regions: 2015 VS 2019 VS 2025
1.4.2 Global Market Size of Schizophrenia Therapeutics (2015-2025)
1.4.3 North America (USA, Canada and Mexico) Schizophrenia Therapeutics Status and Prospect (2015-2025)
1.4.4 Europe (Germany, France, UK, Russia and Italy) Schizophrenia Therapeutics Status and Prospect (2015-2025)
1.4.5 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Schizophrenia Therapeutics Status and Prospect (2015-2025)
1.4.6 South America (Brazil, Argentina, Colombia) Schizophrenia Therapeutics Status and Prospect (2015-2025)
1.4.7 Middle East & Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Schizophrenia Therapeutics Status and Prospect (2015-2025)
2 Company Profiles
2.1 AstraZeneca
2.1.1 AstraZeneca Details
2.1.2 AstraZeneca Major Business and Total Revenue (Financial Highlights) Analysis
2.1.3 AstraZeneca SWOT Analysis
2.1.4 AstraZeneca Product and Services
2.1.5 AstraZeneca Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business and Total Revenue (Financial Highlights) Analysis
2.2.3 Bristol-Myers Squibb SWOT Analysis
2.2.4 Bristol-Myers Squibb Product and Services
2.2.5 Bristol-Myers Squibb Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business and Total Revenue (Financial Highlights) Analysis
2.3.3 Johnson & Johnson SWOT Analysis
2.3.4 Johnson & Johnson Product and Services
2.3.5 Johnson & Johnson Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.4 Eli Lilly
2.4.1 Eli Lilly Details
2.4.2 Eli Lilly Major Business and Total Revenue (Financial Highlights) Analysis
2.4.3 Eli Lilly SWOT Analysis
2.4.4 Eli Lilly Product and Services
2.4.5 Eli Lilly Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.5 Amgen
2.5.1 Amgen Details
2.5.2 Amgen Major Business and Total Revenue (Financial Highlights) Analysis
2.5.3 Amgen SWOT Analysis
2.5.4 Amgen Product and Services
2.5.5 Amgen Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.6 GlaxoSmithKline
2.6.1 GlaxoSmithKline Details
2.6.2 GlaxoSmithKline Major Business and Total Revenue (Financial Highlights) Analysis
2.6.3 GlaxoSmithKline SWOT Analysis
2.6.4 GlaxoSmithKline Product and Services
2.6.5 GlaxoSmithKline Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.7 AbbVie
2.7.1 AbbVie Details
2.7.2 AbbVie Major Business and Total Revenue (Financial Highlights) Analysis
2.7.3 AbbVie SWOT Analysis
2.7.4 AbbVie Product and Services
2.7.5 AbbVie Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
2.8 Alkermes
2.8.1 Alkermes Details
2.8.2 Alkermes Major Business and Total Revenue (Financial Highlights) Analysis
2.8.3 Alkermes SWOT Analysis
2.8.4 Alkermes Product and Services
2.8.5 Alkermes Schizophrenia Therapeutics Revenue, Gross Margin and Market Share (2018-2019)
3 Market Competition, by Players
3.1 Global Schizophrenia Therapeutics Revenue and Share by Players (2015-2020)
3.2 Market Concentration Rate
3.2.1 Top 5 Schizophrenia Therapeutics Players Market Share
3.2.2 Top 10 Schizophrenia Therapeutics Players Market Share
3.3 Market Competition Trend
4 Market Size by Regions
4.1 Global Schizophrenia Therapeutics Revenue and Market Share by Regions
4.2 North America Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
4.3 Europe Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
4.4 Asia-Pacific Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
4.5 South America Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
4.6 Middle East & Africa Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
5 North America Schizophrenia Therapeutics Revenue by Countries
5.1 North America Schizophrenia Therapeutics Revenue by Countries (2015-2020)
5.2 USA Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
5.3 Canada Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
5.4 Mexico Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
6 Europe Schizophrenia Therapeutics Revenue by Countries
6.1 Europe Schizophrenia Therapeutics Revenue by Countries (2015-2020)
6.2 Germany Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
6.3 UK Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
6.4 France Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
6.5 Russia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
6.6 Italy Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
7 Asia-Pacific Schizophrenia Therapeutics Revenue by Countries
7.1 Asia-Pacific Schizophrenia Therapeutics Revenue by Countries (2015-2020)
7.2 China Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
7.3 Japan Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
7.4 Korea Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
7.5 India Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
7.6 Southeast Asia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
8 South America Schizophrenia Therapeutics Revenue by Countries
8.1 South America Schizophrenia Therapeutics Revenue by Countries (2015-2020)
8.2 Brazil Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
8.3 Argentina Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
9 Middle East & Africa Revenue Schizophrenia Therapeutics by Countries
9.1 Middle East & Africa Schizophrenia Therapeutics Revenue by Countries (2015-2020)
9.2 Saudi Arabia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
9.3 UAE Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
9.4 Egypt Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
9.5 South Africa Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
10 Market Size Segment by Type
10.1 Global Schizophrenia Therapeutics Revenue and Market Share by Type (2015-2020)
10.2 Global Schizophrenia Therapeutics Market Forecast by Type (2019-2024)
10.3 First-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2025)
10.4 Second-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2025)
10.5 Third-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2025)
11 Global Schizophrenia Therapeutics Market Segment by Application
11.1 Global Schizophrenia Therapeutics Revenue Market Share by Application (2015-2020)
11.2 Schizophrenia Therapeutics Market Forecast by Application (2019-2024)
11.3 Hospitals Revenue Growth (2015-2020)
11.4 Clinics Revenue Growth (2015-2020)
11.5 Other Revenue Growth (2015-2020)
12 Global Schizophrenia Therapeutics Market Size Forecast (2021-2025)
12.1 Global Schizophrenia Therapeutics Market Size Forecast (2021-2025)
12.2 Global Schizophrenia Therapeutics Market Forecast by Regions (2021-2025)
12.3 North America Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
12.4 Europe Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
12.5 Asia-Pacific Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
12.6 South America Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
12.7 Middle East & Africa Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
14.3 Disclaimer
14.4 About US
Table 1. Global Schizophrenia Therapeutics Revenue (USD Million) by Type: 2015 VS 2019 VS 2025
Table 2. Breakdown of Schizophrenia Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 3. Global Schizophrenia Therapeutics Revenue (USD Million) by Application: 2015 VS 2019 VS 2025
Table 4. Global Market Schizophrenia Therapeutics Revenue (Million USD) Comparison by Regions 2015-2025
Table 5. AstraZeneca Corporate Information, Location and Competitors
Table 6. AstraZeneca Schizophrenia Therapeutics Major Business
Table 7. AstraZeneca Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 8. AstraZeneca SWOT Analysis
Table 9. AstraZeneca Schizophrenia Therapeutics Product and Solutions
Table 10. AstraZeneca Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 11. Bristol-Myers Squibb Corporate Information, Location and Competitors
Table 12. Bristol-Myers Squibb Schizophrenia Therapeutics Major Business
Table 13. Bristol-Myers Squibb Schizophrenia Therapeutics Total Revenue (USD Million) (2018-2019)
Table 14. Bristol-Myers Squibb SWOT Analysis
Table 15. Bristol-Myers Squibb Schizophrenia Therapeutics Product and Solutions
Table 16. Bristol-Myers Squibb Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 17. Johnson & Johnson Corporate Information, Location and Competitors
Table 18. Johnson & Johnson Schizophrenia Therapeutics Major Business
Table 19. Johnson & Johnson Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 20. Johnson & Johnson SWOT Analysis
Table 21. Johnson & Johnson Schizophrenia Therapeutics Product and Solutions
Table 22. Johnson & Johnson Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 23. Eli Lilly Corporate Information, Location and Competitors
Table 24. Eli Lilly Schizophrenia Therapeutics Major Business
Table 25. Eli Lilly Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 26. Eli Lilly SWOT Analysis
Table 27. Eli Lilly Schizophrenia Therapeutics Product and Solutions
Table 28. Eli Lilly Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 29. Amgen Corporate Information, Location and Competitors
Table 30. Amgen Schizophrenia Therapeutics Major Business
Table 31. Amgen Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 32. Amgen SWOT Analysis
Table 33. Amgen Schizophrenia Therapeutics Product and Solutions
Table 34. Amgen Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 35. GlaxoSmithKline Corporate Information, Location and Competitors
Table 36. GlaxoSmithKline Schizophrenia Therapeutics Major Business
Table 37. GlaxoSmithKline Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 38. GlaxoSmithKline SWOT Analysis
Table 39. GlaxoSmithKline Schizophrenia Therapeutics Product and Solutions
Table 40. GlaxoSmithKline Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 41. AbbVie Corporate Information, Location and Competitors
Table 42. AbbVie Schizophrenia Therapeutics Major Business
Table 43. AbbVie Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 44. AbbVie SWOT Analysis
Table 45. AbbVie Schizophrenia Therapeutics Product and Solutions
Table 46. AbbVie Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 47. Alkermes Corporate Information, Location and Competitors
Table 48. Alkermes Schizophrenia Therapeutics Major Business
Table 49. Alkermes Schizophrenia Therapeutics Total Revenue (USD Million) (2017-2018)
Table 50. Alkermes SWOT Analysis
Table 51. Alkermes Schizophrenia Therapeutics Product and Solutions
Table 52. Alkermes Schizophrenia Therapeutics Revenue (USD Million), Gross Margin and Market Share (2018-2019)
Table 53. Global Schizophrenia Therapeutics Revenue (Million USD) by Players (2015-2020)
Table 54. Global Schizophrenia Therapeutics Revenue Share by Players (2015-2020)
Table 55. Global Schizophrenia Therapeutics Revenue (Million USD) by Regions (2015-2020)
Table 56. Global Schizophrenia Therapeutics Revenue Market Share by Regions (2015-2020)
Table 57. North America Schizophrenia Therapeutics Revenue by Countries (2015-2020)
Table 58. North America Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 59. Europe Schizophrenia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 60. Asia-Pacific Schizophrenia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 61. South America Schizophrenia Therapeutics Revenue by Countries (2015-2020)
Table 62. South America Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 63. Middle East and Africa Schizophrenia Therapeutics Revenue (Million USD) by Countries (2015-2020)
Table 64. Middle East and Africa Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Table 65. Global Schizophrenia Therapeutics Revenue (Million USD) by Type (2015-2020)
Table 66. Global Schizophrenia Therapeutics Revenue Share by Type (2015-2020)
Table 67. Global Schizophrenia Therapeutics Revenue Forecast by Type (2021-2025)
Table 68. Global Schizophrenia Therapeutics Revenue by Application (2015-2020)
Table 69. Global Schizophrenia Therapeutics Revenue Share by Application (2015-2020)
Table 70. Global Schizophrenia Therapeutics Revenue Forecast by Application (2021-2025)
Table 71. Global Schizophrenia Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
List of Figures
Figure 1. Schizophrenia Therapeutics Picture
Figure 2. Global Schizophrenia Therapeutics Revenue Market Share by Type in 2019
Figure 3. First-Generation Antipsychotic Drugs Picture
Figure 4. Second-Generation Antipsychotic Drugs Picture
Figure 5. Third-Generation Antipsychotic Drugs Picture
Figure 6. Schizophrenia Therapeutics Revenue Market Share by Application in 2019
Figure 7. Hospitals Picture
Figure 8. Clinics Picture
Figure 9. Other Picture
Figure 10. Global Schizophrenia Therapeutics Revenue (USD Million) and Growth Rate (2015-2025)
Figure 11. North America Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 12. Europe Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 13. Asia-Pacific Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 14. South America Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 15. Middle East and Africa Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 16. Global Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (2015-2025)
Figure 17. Global Schizophrenia Therapeutics Revenue Share by Players in 2019
Figure 18. Global Top 5 Players Schizophrenia Therapeutics Revenue Market Share in 2019
Figure 19. Global Top 10 Players Schizophrenia Therapeutics Revenue Market Share in 2019
Figure 20. Key Players Market Share Trend
Figure 21. Global Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate (%) (2015-2020)
Figure 22. Global Schizophrenia Therapeutics Revenue Market Share by Regions (2015-2020)
Figure 23. Global Schizophrenia Therapeutics Revenue Market Share by Regions in 2018
Figure 24. North America Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 25. Europe Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 26. Asia-Pacific Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 27. South America Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 28. Middle East and Africa Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 29. North America Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 30. North America Schizophrenia Therapeutics Revenue Market Share by Countries in 2019
Figure 31. USA Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 32. Canada Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 33. Mexico Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 34. Europe Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 35. Europe Schizophrenia Therapeutics Revenue Market Share by Countries in 2019
Figure 36. Germany Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 37. UK Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 38. France Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 39. Russia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 40. Italy Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 41. Asia-Pacific Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 42. Asia-Pacific Schizophrenia Therapeutics Revenue Market Share by Countries in 2019
Figure 43. China Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 44. Japan Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 45. Korea Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 46. India Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 47. Southeast Asia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 48. South America Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 49. South America Schizophrenia Therapeutics Revenue Market Share by Countries in 2019
Figure 50. Brazil Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 51. Argentina Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 52. Middle East and Africa Schizophrenia Therapeutics Revenue Market Share by Countries (2015-2020)
Figure 53. Middle East and Africa Schizophrenia Therapeutics Revenue Market Share by Countries in 2019
Figure 54. Saudi Arabia Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 55. UAE Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 56. Egypt Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 57. South Africa Schizophrenia Therapeutics Revenue and Growth Rate (2015-2020)
Figure 58. Global Schizophrenia Therapeutics Revenue Share by Type (2015-2020)
Figure 59. Global Schizophrenia Therapeutics Revenue Share by Type in 2019
Figure 60. Global Schizophrenia Therapeutics Market Share Forecast by Type (2021-2025)
Figure 61. Global First-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2020)
Figure 62. Global Second-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2020)
Figure 63. Global Third-Generation Antipsychotic Drugs Revenue Growth Rate (2015-2020)
Figure 64. Global Schizophrenia Therapeutics Revenue Share by Application (2015-2020)
Figure 65. Global Schizophrenia Therapeutics Revenue Share by Application in 2019
Figure 66. Global Schizophrenia Therapeutics Market Share Forecast by Application (2021-2025)
Figure 67. Global Hospitals Revenue Growth Rate (2015-2020)
Figure 68. Global Clinics Revenue Growth Rate (2015-2020)
Figure 69. Global Other Revenue Growth Rate (2015-2020)
Figure 70. Global Schizophrenia Therapeutics Revenue (Million USD) and Growth Rate Forecast (2021-2025)
Figure 71. Global Schizophrenia Therapeutics Revenue (Million USD) Forecast by Regions (2021-2025)
Figure 72. Global Schizophrenia Therapeutics Revenue Market Share Forecast by Regions (2021-2025)
Figure 73. North America Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
Figure 74. Europe Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
Figure 75. Asia-Pacific Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
Figure 76. South America Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
Figure 77. Middle East and Africa Schizophrenia Therapeutics Revenue Market Forecast (2021-2025)
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
統合失調症治療の世界市場（～2026年） Schizophrenia is a mental disorder characterized by abnormal behavior and failure to understand reality. The schizophrenia treatment market is expected to witness a high growth over the forecast period owing to the increasing incidence of schizophrenia. Market Analysis and Insights: Global Schizophr…- 統合失調症治療薬の世界市場（～2026年） Market Analysis and Insights: Global Schizophrenia Drugs Market The global Schizophrenia Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Schizophrenia Drugs Scope and Market Size Schizophrenia Drugs market is seg…
- 抗精神病薬の世界市場（～2026年） Antipsychotics, also known as neuroleptics or major tranquilizers, are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. During 2016, the second-generation antipsychotic d…
- 次世代抗体療法の世界市場（～2026年） The ADCs segment held the largest market share in the historical period and is projected to hold a market share of over 50% by 2025. The Fc engineered antibodies segmented is projected to witness the fastest growth during the forecast period. Market Analysis and Insights: Global Next Generation Anti…
- 頭頸部がん治療薬/治療の世界市場（～2026年） Head and neck cancer is a group of cancers that starts in the mouth, nose, throat, larynx, sinuses, or salivary glands. Current trends indicate that rising geriatric population worldwide, growing cases of target diseases, and availability of improved healthcare services due to government and private…